Hope S Rugo (Hope Rugo, H S Rugo)

Publication Activity (10 Years)

Years Active: 2017-2023
Publications (10 Years): 57

Top Topics

Clinical Practice

Metastatic Breast Cancer

Top Venues

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

NPJ breast cancer

Breast cancer research and treatment

This page only lists publications with an associated author ORCID identifier.

Publications

Hope S Rugo, Aditya Bardia, Sara M Tolaney
Reply to G.-F. Li et al, K. Altundag, and N. SG et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 41 (8) (2023)
Giuseppe Curigliano, Geoffrey I Shapiro, Rebecca S Kristeleit, Albiruni R Abdul Razak, Stephen Leong, Maria Alsina, Antonio Giordano, Karen A Gelmon, Erica Stringer-Reasor, Ulka N Vaishampayan, Mark Ross Middleton, Anthony J Olszanski, Hope S Rugo, Kenneth A Kern, Nuzhat Pathan, Rachelle Perea, Kristen J Pierce, Sarah C Mutka, Zev A Wainberg
Correction to: A Phase 1B open-label study of gedatolisib (PF-05212384) in combination with other anti-tumour agents for patients with advanced solid tumours and triple-negative breast cancer. British journal of cancer (2023)
William J Gradishar, Ruth M O'Regan, Mothaffar F Rimawi, Jeffrey L Nordstrom, Minori K Rosales, Hope S Rugo
Margetuximab in HER2-positive metastatic breast cancer. Future oncology (London, England) (2023)
Laura A Huppert, Ozge Gumusay, Dame Idossa, Hope S Rugo
Systemic therapy for hormone receptor-positive/human epidermal growth factor receptor 2-negative early stage and metastatic breast cancer. CA: a cancer journal for clinicians (2023)
Hope S Rugo, Xianchen Liu, Benjamin Li, Lynn McRoy, Connie Chen, Rachel M Layman, Adam Brufsky
Real-world treatment patterns for palbociclib plus an aromatase inhibitor, or an aromatase inhibitor alone, for patients with metastatic breast cancer in the Flatiron Database. International journal of cancer (2023)
Sherene Loi, Roberto Salgado, Thomas Powles, Javier Cortes, David W Cescon, Eric P Winer, Deborah L Toppmeyer, Hope S Rugo, Michelino De Laurentiis, Rita Nanda, Hiroji Iwata, Ahmad Awada, Antoinette R Tan, Yuan Sun, Vassiliki Karantza, Anran Wang, Lingkang Huang, Assieh Saadatpour, Razvan Cristescu, Jennifer Yearley, Jared Lunceford, Petar Jelinic, Sylvia Adams
Association Between Biomarkers and Clinical Outcomes of Pembrolizumab Monotherapy in Patients With Metastatic Triple-Negative Breast Cancer: KEYNOTE-086 Exploratory Analysis. JCO precision oncology 7 (2023)
Hope S Rugo, Aditya Bardia, Sara M Tolaney
Reply to G.-F. Li et al, K. Altundag, and N. SG et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 41 (8) (2023)
Sherene Loi, Roberto Salgado, Thomas Powles, Javier Cortes, David W Cescon, Eric P Winer, Deborah L Toppmeyer, Hope S Rugo, Michelino De Laurentiis, Rita Nanda, Hiroji Iwata, Ahmad Awada, Antoinette R Tan, Yuan Sun, Vassiliki Karantza, Anran Wang, Lingkang Huang, Assieh Saadatpour, Razvan Cristescu, Jennifer Yearley, Jared Lunceford, Petar Jelinic, Sylvia Adams
Association Between Biomarkers and Clinical Outcomes of Pembrolizumab Monotherapy in Patients With Metastatic Triple-Negative Breast Cancer: KEYNOTE-086 Exploratory Analysis. JCO precision oncology 7 (2023)
Nicholas C Turner, A Douglas Laird, Melinda L Telli, Hope S Rugo, Audrey Mailliez, Johannes Ettl, Eva-Maria Grischke, Lida A Mina, Judith Balmaña, Peter Andreas Fasching, Sara Alsterlind Hurvitz, Julia F Hopkins, Lee A Albacker, Jijumon Chelliserry, Ying Chen, Umberto Conte, Andrew M Wardley, Mark E Robson
Genomic analysis of advanced breast cancer tumors from talazoparib-treated gBRCA1/2mut carriers in the ABRAZO study. NPJ breast cancer 9 (1) (2023)
K W Im, L A Huppert, L Malevanchik, Hope S Rugo, A J Combes, Michael J Campbell, M F Krummel, M E Melisko
High-dimensional immune cell profiling of cerebrospinal fluid from patients with metastatic breast cancer and leptomeningeal disease. NPJ breast cancer 9 (1) (2023)
Laura A Huppert, Hope S Rugo
Can We De-escalate Therapy for HER2-Positive Metastatic Breast Cancer? Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
Saya L Jacob, Laura A Huppert, Hope S Rugo
Role of Immunotherapy in Breast Cancer. JCO oncology practice (2023)
Fatima Cardoso, Julie Rihani, Victoria Harmer, Nadia Harbeck, Ana Casas, Hope S Rugo, Peter A Fasching, Adam Moore, Joanna de Courcy, Purnima Pathak, Sina Haftchenary, Dawn Aubel, Eva Schumacher-Wulf
Quality of Life and Treatment-Related Side Effects in Patients With HR+/HER2- Advanced Breast Cancer: Findings From a Multicountry Survey. The oncologist (2023)
Hope S Rugo, Xianchen Liu, Benjamin Li, Lynn McRoy, Connie Chen, Rachel M Layman, Adam M Brufsky
Real-World Effectiveness of Palbociclib Plus Aromatase Inhibitors in African American Patients With Metastatic Breast Cancer. The oncologist (2023)
Hope S Rugo, Christine L Crossno, Yaron B Gesthalter, Kristen Kelley, Heather B Moore, Mothaffar F Rimawi, Kelly E Westbrook, Saundra S Buys
Real-World Perspectives and Practices for Pneumonitis/Interstitial Lung Disease Associated With Trastuzumab Deruxtecan Use in Human Epidermal Growth Factor Receptor 2-Expressing Metastatic Breast Cancer. JCO oncology practice (2023)
Jennifer K Litton, Meredith M Regan, Lajos Pusztai, Hope S Rugo, Sara M Tolaney, Elizabeth Garrett-Mayer, Laleh Amiri-Kordestani, Reva K Basho, Ana F Best, Jean-Francois Boileau, Carsten Denkert, Jared C Foster, Nadia Harbeck, Heather A Jacene, Tari A King, Ginny Mason, Ciara Catherine O'Sullivan, Tatiana M Prowell, Andrea L Richardson, Karla A Sepulveda, Mary Lou Smith, Judy A Tjoe, Gulisa Turashvili, Wendy A Woodward, Lynn Pearson Butler, Elena I Schwartz, Larissa A Korde
Standardized Definitions for Efficacy End Points in Neoadjuvant Breast Cancer Clinical Trials: NeoSTEEP. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
Ozge Gumusay, Laura A Huppert, Mark Jesus M Magbanua, Chiara A Wabl, Michael Assefa, Amy Jo Chien, Michelle E Melisko, Melanie C Majure, Mark Moasser, John Park, Hope S Rugo
A phase Ib/II study of eribulin in combination with cyclophosphamide in patients with advanced breast cancer. Breast cancer research and treatment (2023)
Hope S Rugo, Aditya Bardia, Sara M Tolaney
Reply to G.-F. Li et al, K. Altundag, and N. SG et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
Helena Record, Elle Clelland, Harriet T Rothschild, Mandeep Kaur, A Jo Chien, Michelle Melisko, Hope S Rugo, Firdows Mujir, Laura Huppert, Rita A Mukhtar
Tamoxifen or aromatase inhibitors with ovarian function suppression in pre-menopausal stage I-III lobular breast cancer. NPJ breast cancer 9 (1) (2023)
Hope S Rugo, Adam M Brufsky, Xianchen Liu, Benjamin Li, Lynn McRoy, Connie Chen, Rachel M Layman, Massimo Cristofanilli, Mylin A Torres, Giuseppe Curigliano, Richard S Finn, Angela DeMichele
Real-world study of overall survival with palbociclib plus aromatase inhibitor in HR+/HER2- metastatic breast cancer. NPJ breast cancer 8 (1) (2022)
Julie E Lang, Andres Forero-Torres, Douglas Yee, Christina Yau, Denise Wolf, John Park, Barbara A Parker, A Jo Chien, Anne M Wallace, Rashmi Murthy, Kathy S Albain, Erin D Ellis, Heather Beckwith, Barbara B Haley, Anthony D Elias, Judy C Boughey, Rachel L Yung, Claudine Isaacs, Amy S Clark, Hyo S Han, Rita Nanda, Qamar J Khan, Kristen K Edmiston, Erica Stringer-Reasor, Elissa Price, Bonnie Joe, Minetta C Liu, Lamorna Brown Swigart, Emanuel F Petricoin, Julia D Wulfkuhle, Meredith Buxton, Julia L Clennell, Ashish Sanil, Scott Berry, Smita M Asare, Amy Wilson, Gillian L Hirst, Ruby Singhrao, Adam L Asare, Jeffrey B Matthews, Michelle Melisko, Jane Perlmutter, Hope S Rugo, William Fraser Symmans, Laura van 't Veer, Nola M Hylton, Angela M DeMichele, Donald A Berry, Laura J Esserman
Safety and efficacy of HSP90 inhibitor ganetespib for neoadjuvant treatment of stage II/III breast cancer. NPJ breast cancer 8 (1) (2022)
Joyce V Lee, Filomena Housley, Christina Yau, Rachel Nakagawa, Juliane Winkler, Johanna M Anttila, Pauliina M Munne, Mariel Savelius, Kathleen E Houlahan, Daniel Van de Mark, Golzar Hemmati, Grace A Hernandez, Yibing Zhang, Susan Samson, Carole Baas, Marleen Kok, Laura J Esserman, Laura van 't Veer, Hope S Rugo, Christina Curtis, Juha Klefström, Mehrdad Matloubian, Andrei Goga
Author Correction: Combinatorial immunotherapies overcome MYC-driven immune evasion in triple negative breast cancer. Nature communications 13 (1) (2022)
Jung-Tung Hung, I-Ju Chen, Shir-Hwa Ueng, Chiun-Sheng Huang, Shin-Cheh Chen, Mu-Yi Chen, Yung-Chang Lin, Yung-Chang Lin, Michael J Campbell, Hope S Rugo, Alice Lin-Tsing Yu
The clinical relevance of humoral immune responses to Globo H-KLH vaccine adagloxad simolenin (OBI-822)/OBI-821 and expression of Globo H in metastatic breast cancer. Journal for immunotherapy of cancer 10 (6) (2022)
Hope S Rugo, Javier Cortes, Carlos H Barrios, Paula Cabrera, Binghe Xu, Chiun-Sheng Huang, Sung-Bae Kim, Michelle Melisko, Rita Nanda, Tadeusz Pieńkowski, Bernardo L Rapoport, Richard Schwab
GLORIA: phase III, open-label study of adagloxad simolenin/OBI-821 in patients with high-risk triple-negative breast cancer. Future oncology (London, England) (2022)
Hope S Rugo, Aditya Bardia, Frederic Marmé, Javier Cortes, Peter Schmid, Delphine Loirat, Olivier Trédan, Eva Ciruelos Gil, Florence Dalenc, Patricia Gómez Pardo, Komal L Jhaveri, Rosemary Delaney, Olivia Fu, Lanjia Lin, Wendy Verret, Sara M Tolaney
Sacituzumab Govitecan in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 40 (29) (2022)
Giuseppe Curigliano, Geoffrey I Shapiro, Rebecca S Kristeleit, Albiruni R Abdul Razak, Stephen Leong, Maria Alsina, Antonio Giordano, Karen A Gelmon, Erica Stringer-Reasor, Ulka N Vaishampayan, Mark Ross Middleton, Anthony J Olszanski, Hope S Rugo, Kenneth A Kern, Nuzhat Pathan, Rachelle Perea, Kristen J Pierce, Sarah C Mutka, Zev A Wainberg
A Phase 1B open-label study of gedatolisib (PF-05212384) in combination with other anti-tumour agents for patients with advanced solid tumours and triple-negative breast cancer. British journal of cancer (2022)
Hope S Rugo, Kira Raskina, Alexa B Schrock, Russell W Madison, Ryon P Graf, Ethan S Sokol, Smruthy S Sivakumar, Jessica K Lee, Virginia Fisher, Geoffrey R Oxnard, Hanna Tukachinsky
Biology and targetability of the extended spectrum of PIK3CA mutations (PIK3CAm) detected in breast carcinoma. Clinical cancer research : an official journal of the American Association for Cancer Research (2022)
Shom Goel, Antoinette R Tan, Hope S Rugo, Philippe Aftimos, Zoran Andrić, Andrew P Beelen, Jingshan Zhang, John S Yi, Rajesh K Malik, Joyce O'Shaughnessy
Trilaciclib prior to gemcitabine plus carboplatin for metastatic triple-negative breast cancer: phase III PRESERVE 2. Future oncology (London, England) (2022)
Leisha A Emens, Sylvia Adams, Ashley Cimino-Mathews, Mary L Disis, Margaret E Gatti-Mays, Alice Y Ho, Kevin Kalinsky, Heather L McArthur, Elizabeth A Mittendorf, Rita Nanda, David B Page, Hope S Rugo, Krista M Rubin, Hatem Soliman, Patricia A Spears, Sara M Tolaney, Jennifer K Litton
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of breast cancer. Journal for immunotherapy of cancer 9 (8) (2022)
Hope S Rugo, Sara M Tolaney, Delphine Loirat, Kevin Punie, Aditya Bardia, Sara Alsterlind Hurvitz, Joyce O'Shaughnessy, Javier Cortes, Véronique Diéras, Lisa Anne Carey, Luca Gianni, Martine J Piccart, Sibylle Loibl, David M Goldenberg, Quan Hong, Martin Olivo, Loretta M Itri, Kevin Kalinsky
Safety analyses from the phase 3 ASCENT trial of sacituzumab govitecan in metastatic triple-negative breast cancer. NPJ breast cancer 8 (1) (2022)
Hope S Rugo, Seock-Ah Im, Fatima Cardoso, Javier Cortes, Giuseppe Curigliano, Antonino Musolino, Mark D Pegram, Thomas Bachelot, Gail S Wright, Cristina Saura, Santiago Escrivá-de-Romaní, Michelino De Laurentiis, Gary N Schwartz, Timothy J Pluard, Francesco Ricci, William R Gwin, Christelle Levy, Ursa Brown-Glaberman, Jean-Marc Ferrero, Maaike de Boer, Sung-Bae Kim, Katarína Petráková, Denise A Yardley, Orit Freedman, Erik H Jakobsen, Einav Nili Gal-Yam, Rinat Yerushalmi, Peter Andreas Fasching, Peter A Kaufman, Emily J Ashley, Raul Perez-Olle, Shengyan Hong, Minori Koshiji Rosales, William J Gradishar, null null
Margetuximab Versus Trastuzumab in Patients With Previously Treated HER2-Positive Advanced Breast Cancer (SOPHIA): Final Overall Survival Results From a Randomized Phase 3 Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022)
Hope S Rugo, Peter Kabos, J Thad Beck, Guy Jerusalem, Hans P M W Wildiers, Elena Sevillano, Luis Paz-Ares, Michael J Chisamore, Sonya C Chapman, Anwar M Hossain, Yanyun Chen, Sara M Tolaney
Abemaciclib in combination with pembrolizumab for HR+, HER2- metastatic breast cancer: Phase 1b study. NPJ breast cancer 8 (1) (2022)
Alexandra C Apple, Cutter A Lindbergh, Susan M Landau, Amy DeLuca, Jamie L Eberling, William J Jagust, Joel H Kramer, Hope S Rugo, Lara H Heflin
Longitudinal Trajectories of Memory Performance in Patients with Early-Stage Breast Cancer. Journal of oncology 2022 (2022)
Hope S Rugo, Gerardo A Umanzor, Min-Fun R Kwan, David L Cutler
Reply to Z.R. McCaw et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022)
Tam Binh V Bui, Boudewijn M T Burgering, Andrei Goga, Hope S Rugo, Laura van 't Veer
Biomarkers for Cyclin-Dependent Kinase 4/6 Inhibitors in the Treatment of Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced/Metastatic Breast Cancer: Translation to Clinical Practice. JCO precision oncology 6 (2022)
Joyce V Lee, Filomena Housley, Christina Yau, Rachel Nakagawa, Juliane Winkler, Johanna M Anttila, Pauliina M Munne, Mariel Savelius, Kathleen E Houlahan, Daniel Van de Mark, Golzar Hemmati, Grace A Hernandez, Yibing Zhang, Susan Samson, Carole Baas, Marleen Kok, Laura J Esserman, Laura van 't Veer, Hope S Rugo, Christina Curtis, Juha Klefström, Mehrdad Matloubian, Andrei Goga
Combinatorial immunotherapies overcome MYC-driven immune evasion in triple negative breast cancer. Nature communications 13 (1) (2022)
Hala T Borno, Mi-Ok Kim, Julian C Hong, Sasha Yousefi, Amy Lin, Irina Tolstykh, Sylvia Zhang, Rana R McKay, Olivier Harismendy, Pelin Cinar, Hope S Rugo, Vadim S Koshkin, Maya Rabow, Christine Wang, Adina Bailey, Eric J Small
COVID-19 Outcomes Among Patients With Cancer: Observations From the University of California Cancer Consortium COVID-19 Project Outcomes Registry. The oncologist 27 (5) (2022)
Antonino Musolino, William J Gradishar, Hope S Rugo, Jeffrey L Nordstrom, Edwin P Rock, Fernanda Arnaldez, Mark D Pegram
Role of Fcγ receptors in HER2-targeted breast cancer therapy. Journal for immunotherapy of cancer 10 (1) (2022)
Hope S Rugo, Gerardo A Umanzor, Francisco J Barrios, Rosa H Vasallo, Marco A Chivalan, Suyapa Bejarano, Julio R Ramírez, Luis Fein, Ruben D Kowalyszyn, E Douglas Kramer, Hui Wang, Min-Fun R Kwan, David L Cutler, null null
Open-Label, Randomized, Multicenter, Phase III Study Comparing Oral Paclitaxel Plus Encequidar Versus Intravenous Paclitaxel in Patients With Metastatic Breast Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022)
Saumya Umashankar, Matina Elise Mamounas, Madeline B Matthys, Edward Kenji Hadeler, Emily Claire Wong, Greg Hicks, Jimmy Hwang, Amy Jo Chien, Hope S Rugo, Deborah Hamolsky, Laura J Esserman, Michelle E Melisko
Evaluation of the Pathways for Survivors Program to Address Breast Cancer Survivorship-Associated Distress: Survey Study. JMIR cancer 8 (1) (2022)
Sara M Tolaney, Nabihah Tayob, Chau Dang, Denise A Yardley, Steven Jay Isakoff, Vicente Valero, Meredith Faggen, Therese Marie Mulvey, Ron Bose, Jiani Hu, Douglas Weckstein, Antonio C Wolff, Katherine E Reeder-Hayes, Hope S Rugo, Bhuvaneswari Ramaswamy, Dan Zuckerman, Lowell Hart, Vijayakrishna K Gadi, Michael Constantine, Kit Cheng, Frederick Briccetti, Bryan Paul Schneider, Audrey Merrill Garrett, P Kelly Marcom, Kathy S Albain, Patricia DeFusco, Nadine M Tung, Blair Ardman, Rita Nanda, Rachel C Jankowitz, Mothaffar F Rimawi, Vandana G Abramson, Paula R Pohlmann, Catherine H Van Poznak, Andres Forero-Torres, Minetta C Liu, Kathryn J Ruddy, Yue Zheng, Shoshana M Rosenberg, Richard D Gelber, Lorenzo Trippa, William Barry, Michelle DeMeo, Harold Burstein, Ann H Partridge, Eric P Winer, Ian E Krop
Adjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT): A Randomized Clinical Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 39 (21) (2021)
Amy S Clark, Christina Yau, Denise M Wolf, Emanuel F Petricoin, Laura van 't Veer, Douglas Yee, Stacy L Moulder, Anne M Wallace, A Jo Chien, Claudine Isaacs, Judy C Boughey, Kathy S Albain, Kathleen Kemmer, Barbara B Haley, Hyo S Han, Andres Forero-Torres, Anthony Elias, Julie E Lang, Erin D Ellis, Rachel Yung, Debasish Tripathy, Rita Nanda, Julia D Wulfkuhle, Lamorna Brown Swigart, Rosa I Gallagher, Teresa Helsten, Erin Roesch, Cheryl A Ewing, Michael Alvarado, Erin P Crane, Meredith Buxton, Julia L Clennell, Melissa Paoloni, Smita M Asare, Amy Wilson, Gillian L Hirst, Ruby Singhrao, Katherine Steeg, Adam Asare, Jeffrey B Matthews, Scott Berry, Ashish Sanil, Michelle Melisko, Jane Perlmutter, Hope S Rugo, Richard B Schwab, William Fraser Symmans, Nola M Hylton, Donald A Berry, Laura J Esserman, Angela M DeMichele
Neoadjuvant T-DM1/pertuzumab and paclitaxel/trastuzumab/pertuzumab for HER2+ breast cancer in the adaptively randomized I-SPY2 trial. Nature communications 12 (1) (2021)
Sibylle Loibl, Frederic Marmé, Miguel Martin, Michael Untch, Hervé R Bonnefoi, Sung-Bae Kim, Harry Bear, Nicole McCarthy, Mireia Melé Olivé, Karen Gelmon, José García-Sáenz, Catherine M Kelly, Toralf Reimer, Masakazu Toi, Hope S Rugo, Carsten Denkert, Michael Gnant, Andreas Makris, Maria Koehler, Cynthia Huang-Bartelett, Maria Jose Lechuga Frean, Marco Colleoni, Gustavo Werutsky, Sabine Seiler, Nicole Burchardi, Valentina Nekljudova, Gunter von Minckwitz
Palbociclib for Residual High-Risk Invasive HR-Positive and HER2-Negative Early Breast Cancer-The Penelope-B Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 39 (14) (2021)
Stuart Turner, Stephen Chia, Hemanth Kanakamedala, Wei-Chun Hsu, Jinhee Park, David Chandiwana, Antonia Ridolfi, Chu-Ling Yu, Juan Pablo Zarate, Hope S Rugo
Effectiveness of Alpelisib + Fulvestrant Compared with Real-World Standard Treatment Among Patients with HR+, HER2-, PIK3CA-Mutated Breast Cancer. The oncologist 26 (7) (2021)
Michael Gnant, Amylou C Dueck, Sophie Frantal, Miguel Martin, Hal J Burstein, Richard Greil, Peter Fox, Antonio C Wolff, Arlene Chan, Eric P Winer, Georg Pfeiler, Kathy D Miller, Marco Colleoni, Jennifer M Suga, Gabor Rubovsky, Judith M Bliss, Ingrid A Mayer, Christian F Singer, Zbigniew Nowecki, Olwen Hahn, Jacqui Thomson, Norman Wolmark, Kepa Amillano, Hope S Rugo, Guenther G Steger, Blanca Hernando Fernández de Aránguiz, Tufia C Haddad, Antonia Perelló, Meritxell Bellet, Hannes Fohler, Otto Metzger Filho, Anita Jallitsch-Halper, Kadine Solomon, Céline Schurmans, Kathy P Theall, Dongrui Ray Lu, Kathleen Tenner, Christian Fesl, Angela M DeMichele, Erica L Mayer, null null
Adjuvant Palbociclib for Early Breast Cancer: The PALLAS Trial Results (ABCSG-42/AFT-05/BIG-14-03). Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2021)
Hope S Rugo, Eduardo J Pennella, Unmesh Gopalakrishnan, Miguel Hernandez-Bronchud, Jay Herson, Hans Friedrich Koch, Subramanian Loganathan, Sarika Deodhar, Ashwani Marwah, Alexey Manikhas, Igor Bondarenko, Guzel Mukhametshina, Gia Nemsadze, Joseph D Parra, Maria Luisa T Abesamis-Tiambeng, Kakhaber Baramidze, Charuwan Akewanlop, Ihor Vynnychenko, Virote Sriuranpong, Gopichand Mamillapalli, Sirshendu Roy, Eduardo Patricio Yanez Ruiz, Abhijit Barve, Adolfo Fuentes-Alburo, Cornelius F Waller
Final overall survival analysis of the phase 3 HERITAGE study demonstrates equivalence of trastuzumab-dkst to trastuzumab in HER2-positive metastatic breast cancer. Breast cancer research and treatment 188 (2) (2021)
Hope S Rugo, Anja Haltner, Lin Zhan, Anh Tran, Eustratios Bananis, Becky Hooper, Debanjali Mitra, Chris Cameron
Matching-adjusted indirect comparison of palbociclib versus ribociclib and abemaciclib in hormone receptor-positive/HER2-negative advanced breast cancer. Journal of comparative effectiveness research 10 (6) (2021)
Hope S Rugo, Jens Huober, Jose A Garcia-Saenz, Norikazu Masuda, Joo Hyuk Sohn, Valerie A M Andre, Susana Barriga, Joanne Cox, Matthew Goetz
In Reply. The oncologist 26 (7) (2021)
Eva Maria Ciruelos, Hope S Rugo, Ingrid A Mayer, Christelle Levy, Frédéric Forget, Juan Ignacio Delgado Mingorance, Tamar Safra, Norikazu Masuda, Yeon Hee Park, Dejan Juric, PierFranco Conte, Mario Campone, Sibylle Loibl, Hiroji Iwata, Xiaolei Zhou, Jinhee Park, Antonia Ridolfi, Ines Lorenzo, Fabrice Andre
Patient-Reported Outcomes in Patients With PIK3CA-Mutated Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer From SOLAR-1. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 39 (18) (2021)
Harold J Burstein, Mark R Somerfield, Debra L Barton, Ali Dorris, Lesley J Fallowfield, Dharamvir Jain, Stephen R D Johnston, Larissa A Korde, Jennifer K Litton, Erin R Macrae, Lindsay L Peterson, Praveen Vikas, Rachel L Yung, Hope S Rugo
Endocrine Treatment and Targeted Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: ASCO Guideline Update. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 39 (35) (2021)
Chiun-Sheng Huang, Alice L Yu, Ling-Ming Tseng, Louis W C Chow, Ming-Feng Hou, Sara A Hurvitz, Richard B Schwab, James L Murray, Hsien-Kun Chang, Hong-Tai Chang, Shin-Cheh Chen, Sung-Bae Kim, Jung-Tung Hung, Shir-Hwa Ueng, Su-Hua Lee, Chwen-Cheng Chen, Hope S Rugo
Globo H-KLH vaccine adagloxad simolenin (OBI-822)/OBI-821 in patients with metastatic breast cancer: phase II randomized, placebo-controlled study. Journal for immunotherapy of cancer 8 (2) (2021)
Hope S Rugo, Massimo Cristofanilli, Sybille Loibl, Nadia Harbeck, Angela DeMichele, Hiroji Iwata, Yoon Hee Park, Adam Brufsky, Kathy Puyana Theall, Xin Huang, Lynn McRoy, Eustratios Bananis, Nicholas C Turner
Prognostic Factors for Overall Survival in Patients with Hormone Receptor-Positive Advanced Breast Cancer: Analyses From PALOMA-3. The oncologist 26 (8) (2021)
Hope S Rugo, Jens Huober, José A García-Sáenz, Norikazu Masuda, Joo Hyuk Sohn, Valerie A M Andre, Susana Barriga, Joanne Cox, Matthew Goetz
Management of Abemaciclib-Associated Adverse Events in Patients with Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Safety Analysis of MONARCH 2 and MONARCH 3. The oncologist 26 (1) (2020)
Hope S Rugo, Veronique Dieras, Javier Cortes, Debra Patt, Hans Wildiers, Joyce O'Shaughnessy, Esther Zamora, Denise A Yardley, Gebra Cuyun Carter, Kristin M Sheffield, Li Li, Valerie A M Andre, Xiaohong I Li, Martin Frenzel, Yu-Jing Huang, Maura N Dickler, Sara M Tolaney
Real-world survival outcomes of heavily pretreated patients with refractory HR+, HER2-metastatic breast cancer receiving single-agent chemotherapy-a comparison with MONARCH 1. Breast cancer research and treatment 184 (1) (2020)
Hope S Rugo, Jack A Di Palma, Debu Tripathy, Richard Bryce, Susan Moran, Elizabeth Olek, Linda Bosserman
The characterization, management, and future considerations for ErbB-family TKI-associated diarrhea. Breast cancer research and treatment 175 (1) (2019)
Hope S Rugo, Johannes Ettl, Sara Alsterlind Hurvitz, Anthony Gonçalves, Kyung-Hun Lee, Louis Fehrenbacher, Lida A Mina, Sami Diab, Natasha E Woodward, Rinat Yerushalmi, Annabel Goodwin, Joanne L Blum, Miguel Martin, Ruben G W Quek, Iulia Cristina Tudor, Helen Bhattacharyya, Eric Gauthier, Jennifer K Litton, Wolfgang Eiermann
Outcomes in Clinically Relevant Patient Subgroups From the EMBRACA Study: Talazoparib vs Physician's Choice Standard-of-Care Chemotherapy. JNCI cancer spectrum 4 (1) (2019)
Hope S Rugo, Olivier Trédan, Jungsil Ro, Serafin M Morales, Mario Campone, Antonino Musolino, Noémia Afonso, Marta Ferreira, Kyong Hwa Park, Javier Cortes, Antoinette R Tan, Joanne L Blum, Lamar Eaton, Christine K Gause, Zhen Wang, Ellie Im, David J Mauro, Mary Beth Jones, Andrew Denker, José Baselga
A randomized phase II trial of ridaforolimus, dalotuzumab, and exemestane compared with ridaforolimus and exemestane in patients with advanced breast cancer. Breast cancer research and treatment 165 (3) (2017)